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INFLÜENCE OF THE LYSOSOMAL ELASTASE INHIBITOR EGLIN 
ON THE DEVELOPMENT OF INTERSTITIAL LUNG EDEMA 
IN E.COLI BACTEREMIA IN PIGS 
H.F. Welter, M. Siebeck, 0. T h e t t e r , M. Jochum 
Chirurgische K l i n i k Innenstadt und Chirurgische P o l i -
k l i n i k der Universität München, Abteilung für 
K l i n i s c h e Chemie und K l i n i s c h e Biochemie i n der 
Chirurgischen K l i n i k der Universität München 
INTRODUCTION 
The importance of u n s p e c i f i c p r o t e o l y s i s i n inflamma-
tory disease processes i s cu r r e n t l y gaining common i n t e -
r e s t . An imbalance between the endogenous i n h i b i t o r / 
Protease r a t i o i n favour of the proteases might be the 
reason f o r extensive p r o t e o l y s i s of t i s s u e structures and 
humoral factors. E g l i n c, an 8100 Da miniprotein from the 
medical leech, i s a potent i n h i b i t o r of the lysosomal 
proteinases elastase and cathepsin G. Its resistance 
against oxidation and p r o t e o l y s i s (Seemüller et a l . 1981) 
suggested i t s use f o r an a n t i p r o t e o l y t i c therapy. The 
production of s u f f i c i e n t amounts of e g l i n c ( r - e g l i n c) by 
recombinant DNA technology (Rink et a l . 1984) made such 
studies possible. We wanted to examine whether e g l i n medi-
c a t i o n could be of p o t e n t i a l b e n e f i t during a complex 
inflammatory S i t u a t i o n such as an experimentally induced 
E . c o l i septicemia with r e s p i r a t o r y f a i l u r e i n pigs. 
MATERIALS AND METHODS 
Weaned domestic pigs (body weight around 20 kg) spon-
taneously r e s p i r a t i n g under pentobarbital anesthesia were 
used. Catheters were placed to monitor blood pressures, 
c a r d i a c Output and extravascular lung water (EVLW, double 
i n d i c a t o r method, Lewis et a l . 1979) and to c o l l e c t blood 
and urine samples. A l l pigs (n = 14) were given an i n -
122 / Weiteretal 
f u s i o n of 3 x 10 l i v e c e l l s obtained from f r e s h l y 
cultured E . c o l i (ATCC 20399), i n 24 ml s a l i n e o v e r a 
period of 2 hrs. In addition, 7 animals were given 200 ml 
0.9% s a l i n e (group 1) and 7 animals r - e g l i n c i n a dosis 
of 3.85 mg / kg x h i n 200 ml 0.9% s a l i n e (group 2), each 
f o r 4 hrs. A l l intravenous i n f u s i o n s were s t a r t e d s i m u l t a -
neously, 60 min a f t e r the end of the Operation. r - E g l i n c 
concentration i n plasma and urine samples was determined 
by r a d i a l immunodiffusion. Alpha-2-macroglobulin (alpha-2-
M) and antithrombin III (AT III) l e v e l s were estimated by 
chromogenic Substrate assays (Boehringer, Mannheim), 
f a c t o r XIII (F XIII) by a coagulation method (Behring-
werke, Marburg). Observation was terminated at death or 
a f t e r 30 hrs and lung t i s s u e was f i x e d immediately. 
Severity of lung t i s s u e damage was assessed i n hematoxy-
line- e o s i n e stained sections and graded i n t o severe, 
moderate, or absent i n t e r s t i t i a l edema. For comparison of 
lung damage, the Mantel-Haenszel t e s t was used. Unpaired 
data were compared with the t w o - t a i l e d t - t e s t . 
RESULTS 
Antithrombin III and Factor XIII. S i g n i f i c a n t con-
sumption of these proteins was observed i n the bacteremia 
group 1 but was c l e a r l y reduced by administration of r -
e g l i n c (group 2). The mean of the l a s t measured AT I I I 
l e v e l was 80.9 + 12.8% i n group 1 vs. 97.4 + 10% i n 
group 2 (p < 0.02). The mean of the l a s t measured FX I I I 
l e v e l was 53.9 + 15.7% i n group 1 and 76.3 + 13.2% i n 
group 2 (p < 0.015). 
Light microscopical evaluation of long tissue. Severe 
i n t e r s t i t i a l edema (3 cases) or moderate i n t e r s t i t i a l 
edema (4 cases) and accumulation of nucleated c e l l s was 
noted i n a l l t i s s u e sections of group 1 animals. Other 
t y p i c a l features were not constant, e.g. p e r i b r o n c h i a l , 
p e r i v a s c u l a r and a l v e o l a r edema, a t e l e c t a s i s and i n t r a v a s -
c u l a r c l o t formation. In group 2, moderate edema was found 
i n 2 animals and 5 animals showed no sign of increased 
vascular permeability. The d i f f e r e n c e was s i g n i f i c a n t 
(Fisher's exact p < 0.01). 
Plasma levels and urinary excretion of eglin. Maximum 
l e v e l s of r - e g l i n c i n plasma were attained a f t e r 4 hrs 
and ranged from 1.9 to 5.1 umol/1. Plasma l e v e l s remained 
high i n animals with impaired renal e l i m i n a t i o n . In a n i -
mals with normal renal function, maximum plasma l e v e l s 
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r a n g e d f rom 2.9 t o 3.7 u m o l / 1 a n d e g l i n was n o t d e t e c t a b l e 
any more a f t e r 6 t o 12 h r s . I n t h e s e a n i m a l s , 75 u p t o 95% 
of t h e t o t a l a d m i n i s t e r e d e g l i n d o s e s w e r e found i n t h e 
u r i n e w i t h i n 12 h r s . 
Mortality. I n g r o u p 1 , 3 o u t o f 7 a n i m a l s s u r v i v e d 
t h e O b s e r v a t i o n p e r i o d , 4 d i e d a f t e r 3 . 5 , 6 . 7 , 6 . 8 , a n d 
8 . 4 hrs, r e s p e c t i v e l y . I n group 2 , 4 o u t o f 7 a n i m a l s 
survived t h e 30 hrs Observation period, 3 d i e d a f t e r 1 5 . 1 , 
1 5 . 3 and 18.4 hrs, r e s p e c t i v e l y . 
Mean a r t e r i a l blood pressure (AP). I n a l l a n i m a l s , AP 
d r o p p e d i n i t i a l l y by 20 t o 30 mm Hg. H o w e v e r , a f t e r t h e 
f i r s t 2 t o 3 h r s AP r e c o v e r e d i n g r o u p 2 a n i m a l s and 
d e c l i n e d f u r t h e r u n t i l d e a t h i n g r o u p 1 a n i m a l s ( n . s . ) . 
Extravascular lung water« I n g r o u p 1 , EVLW r o s e 
s t e e p l y f rom 16 + 4.2 m l / k g a t z e r o h r s t o 24 + 10 m l / k g 
a t 7 h r s w h e r e a s i t i n c r e a s e d o n l y s l i g h t l y d u r i n g t h i s 
t i m e i n t e r v a l i n g r o u p 2 f r o m 1 3 + 1.8 m l / k g t o 17 + 3 .7 
m l / k g ( n . s . ) . 
Alpha-2-macroglobulin. a l p h a - 2 - M d e c r e a s e d s i g n i f i -
c a n t l y i n a l l e x p e r i m e n t s i n d i c a t i n g a c t i v a t i o n o f p r o t e o -
l y s i s . However , c o n s u m p t i o n o f a l p h a - 2 - M was c o n s i d e r a b l y 
l e s s s e v e r e i n g r o u p 2 a n i m a l s . 
O t h e r parameters. The f o l l o w i n g m e a s u r e m e n t s d i s -
p l a y e d a t y p i c a l r e s p o n s e o f t h e a n i m a l s t o s e p t i c e m i a : 
W h i t e b l o o d c e l l s showed a d e e p i n i t i a l l e u c o c y t o p e n i a 
f o l l o w e d by l e u c o c y t o s i s . P l a t e l e t c o u n t s d r o p p e d t o 11% 
u p t o 50% of t h e s t a r t i n g v a l u e s . A r t e r i a l b l o o d g a s 
a n a l y s e s showed h y p o x e m i a , a c i d o s i s and h y p o c a p n i a . The 
p u l m o n a r y c i r c u l a t i o n r e a c t e d w i t h an e n o r m o u s p u l m o n a r y 
a r t e r i a l h y p e r t e n s i o n a n d d e c r e a s e d c a r d i a c O u t p u t . A l l 
t h e s e p a r a m e t e r s w e r e n o t s u b s t a n t i a l l y i n f l u e n c e d by 
e g l i n a d m i n i s t r a t i o n . U r i n e Output d e c r e a s e d a n d was 
b e t t e r m a i n t a i n e d i n g r o u p 2 t h a n i n g r o u p 1 a n i m a l s . 
DISCUSSION 
The l i g h t m i c r o s c o p i c a l o b s e r v a t i o n s a n d t h e m e a s u r e -
m e n t s of EVLW c l e a r l y i n d i c a t e t h a t t h e a c c u m u l a t i o n o f 
i n t e r s t i t i a l f l u i d c a n b e p r e v e n t e d by r - e g l i n c t r e a t -
m e n t . T h i s f a v o u r s t h e a s s u m p t i o n t h a t a t l e a s t e l a s t a s e 
f r o m p o l y m o r p h o n u c l e a r g r a n u l o c y t e s (PMN) i s i n v o l v e d i n 
t h e p a t h o p h y s i o l o g y o f l u n g t i s s u e d a m a g e d u r i n g s e p t i c -
e m i a (Lee e t a l . 1 9 8 1 ) . AT I I I a n d F X I I I p l a s m a l e v e l s 
w e r e b e t t e r m a i n t a i n e d u n d e r e g l i n t r e a t m e n t . We p r e f e r t o 
i n t e r p r e t t h i s f i n d i n g a s an i n d i c a t i o n o f a n e f f e c t i v e l y 
124 / Welter et al 
i n h i b i t e d u n s p e c i f i c p r o t e o l y s i s ( F r i t z et a l . 1984) 
rather than an i n h i b i t i o n of coagulation. In humans and i n 
dogs, f a t a l septicemia was a l s o associated with an exten-
sive systemic p r o t e o l y s i s as assesssed by F XIII and 
AT III a c t i v i t y i n plasma (Jochum et a l . 1981, Jochum et 
a l . 1984). Correspondingly, protection of these proteins 
from p r o t e o l y s i s as t r i e d i n t h i s study apparently im-
proves prognosis. Alpha-2-M, a potent i n h i b i t o r of various 
lysosomal and other proteinases, i s a l s o a h i g h l y suscep-
t i b l e Substrate f o r both PMN elastase and PMN cathepsin G. 
The observed d i f f e r e n c e between the groups i n the plasma 
l e v e l s of alpha-2-M may be explained therefore by a r e -
duced consumption of t h i s i n h i b i t o r due to the p r o t e c t i v e 
e f f e c t of e g l i n c. Remarkably, e g l i n c l e v e l s i n plasma 
between 2 and 5 umol/1 seem to be s u f f i c i e n t to i n h i b i t 
the l i b e r a t e d lysosomal proteinases s u b s t a n t i a l l y . The 
actual e g l i n c l e v e l i s , however, strongly influenced by 
the kidney function because e l i m i n a t i o n of t h i s i n h i b i t o r 
occurs c h i e f l y by renal excretion. 
SUMMARY 
Infusion of 3 x 1 0 1 0 l i v e E .coli c e l l s i n t o anesthe-
t i z e d p i g l e t s induced severe septicemia with c h a r a c t e r i s -
t i c a l t e r a t i o n s i n systemic and pulmonary c i r c u l a t i o n , 
lung function and morphology, blood c e l l counts and plasma 
pro t e i n composition. The simultaneous i n f u s i o n of the 
elastase-cathepsin G i n h i b i t o r , r - e g l i n c, i n a d o s i s of 
3.85 mg / kg x h f o r 4 hrs, reduced m o r t a l i t y , plasma 
pro t e i n consumption, and accumulation of i n t e r s t i t i a l 
f l u i d i n the lungs. These findings are i n favour of the 
concept that during septicemia the balance between l i b e -
rated lysosomal proteinases and t h e i r e x t r a c e l l u l a r i n h i -
b i t o r s i s severely disturbed. I t can be at l e a s t p a r t i a l l y 
restored by administration of an exogenous elastase i n h i -
b i t o r . 
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Swan-Ganz catheter, 228 
systemic vascular resistance, 216, 
218, 219, 230 
kallikrein-kinin system activation, 212-
215,220, 221,227 
bradykinin, 220-221 
ketanserin, 212, 213, 222, 228 
methylprednisolone, 212, 213, 220-222, 
228 
naloxone, 212, 213, 227, 228 
plasma endotoxin, chromogenic Substrate 
measurement, 213-215 
Protease inhibitors 
antithrombin III, 212, 213, 216, 217, 
220,221,228 
aprotinin, 212, 213, 220, 228 
Cl-esterase inhibitor, 212-213, 220, 
221, 228 
Endotoxemia, thromboxane synthetase inhib-
itors, 328-329 
648 / Index 
Endotoxin (ETX) 
endothelial damage, granulocyte media-
tion of tissue injury, 25-28 
and platelets, 26 
leukotrienes as mediators of shock and 
tissue trauma, rat, 311-316 
MOF, wound inflammatory mediators 
and, 527-532, 534 
myocardial dysfunction in sepsis, 576, 
584 
cell membrane effect, 576 
oxygen radical scavengers, Prophylaxis 
and treatment, 262-264 
receptor competition,lipid X inhibition of 
LPS neutrophil activation, 434 
Salmonella abortus equi, 282 
see also Ebselen (selenium Compound), 
protection vs. endotoxin shock in 
galactosamine-sensitized rodents; 
Ibuprofen effect on ETX-stimula-
ted inflammation 
Endotoxin, cause of mediator release in sep-
sis, overview, 377-389 
B cells, 380 
bolus cf. infusion of pulses, 381-384, 
386, 388 
bradykinin, 380, 385, 387, 388 
cardiac Output, 377, 381-382, 385, 387, 
388 
leukotrienes, rat, 311-316 
lymph flow, 379, 388, 389 
microvascular permeability, 377, 379-
381,387, 388 
shear rate, 387-388 
myocardial depression, 387 
opiates, endogenous, 385, 389 
naloxone, 385, 389 
PMNs, 378, 379, 387, 388 
prostacyclin, 385 
sheep model, 378-380, 384-384 
T cells, 380, 388 
thromboxane, 382 
vascular resistance 
peripheral, 377, 381-382, 385 
systemic, 377 
Endotoxin shock 
dog model (£. coli), 393-398 
arterial pressure, systemic and pulmo-
nary, 394, 395, 398 
cardiac Output, 393-398 
diarrhea, 394, 396 
fluid infusion, 394, 395, 398 
heart rate, 394, 395 
lactate, 394, 3%, 397 
vascular resistance, systemic, 3%, 
397 
ibuprofen, increased survival, 327-330 
see also Prostacyclin, intravenous, in 
endotoxin shock, rabbit; Septic 
shock entries 
Epinephrine (adrenaline), 467, 472, 473 
catecholamines, multiple trauma, and 
ARDS, 478, 483-486 
transmembrane signaling perturbation, 
endotoxemia, rat hepatocyte, 
409-412 
Erythrocytes, catecholamines, multiple 
trauma, and ARDS, 479 
Escherichia coli, 328, 402, 404, 420, 423, 
447 
eglin, elastase inhibitor, and lungedema, 
septic pigs, 121-122 
elastase and leukocyte counts, septic pig 
lung, 116-118 
ETX shock, dog model, 393-398 
MOF, ETX and, 528-529, 531 
see also Cl-esterase inhibitor, early E. 
coli septicemia, pigs; Kallikrein-
kinin system activation, lung, 
E. coli septic sheep 
Esterase stain, leukostasis, quantitative esti-
mation, 45, 49 
Extracorporeal circulation 
biochemical lung monitoring during CPB, 
95-104 
apnoe, 96, 98-100, 103-104 
elastase, granulocyte, 96, 97, 100-104 
lysozyme, 97, 99-100, 104 
NAG, 97-99, 101-104 
PEEP, 96, 98, 100, 103, 104 
vena cava superior cf. left atrium, 
96-98, 101, 102, 104 
kallikrein system activation during CPB, 
87 
MDF release during CPB, 611-619 
see also Cl-esterase inhibitor and elastase 
release, extracorporeal circulation; 
Index / 649 
Kallikrein-kinin system activation 
during aorto-coronary bypass 
(CPB) 
Extravascular lung water 
alveolar cell reactions, posttraumatic lung 
failure and ARDS, 510-512 
burn shock and resuscitation, 548-550 
eglin, elastase inhibitor, and lung edema, 
septic pigs, 123 
leukotriene generation, Polytrauma pa-
tients with ARDS, 312-313 
see also Microvascular permeability, en-
dotoxemia/septic shock 
0-Factor XHa 
Cl-esterase inhibitor and elastase release, 
extracorporeal circulation, 108, 
110 
prekallikrein activation, 93 
Factor XII (Hageman factor), 159, 162, 539, 
540 
Factor Xllf, prekallikrein activation, 93 
Factor XIÜ 
Cl-esterase inhibitor, early E. coli septi-
cemia, pigs, 142, 144 
eglin, elastase inhibitor, and lung edema, 
septic pigs, 122-124 
Fatoxidation, flow or catabolic phase of in-
jury, 464, 465, 469 
Fatty acids, polyunsaturated, 245-246 
4-hydroxynonenal, 246-250 
see also Arachidonic acid entries 
Fibrin 
catecholamines, multiple trauma, and 
ARDS, 480-481 
deposits, glomerular, prostacyclin in ETX 
shock, 371, 374, 375 
Fibrin-neutrophil interactions, lung micro-
vascular injury, 33-41 
HETEs, 40-41 
leukotriene B4, 40-41 
neutrophil 
adherence to endothelium, 40 
aggregation, 39 
Sequestration, lung, 37-39 
permeability, increased, 34-35, 39 
protein exchange, 34, 35, 39 
pulmonary lymph flow, 34, 35, 38-40 
thrombin, 33-41 
chemotactic domain, 33 
himdin, 39 
platelet, response, 35 
Fibrinogen, catecholamines, multiple trauma, 
and ARDS, 480-481 
Fibrinopeptide A, 274 
Flow phase, changes in injury, 463, 465-469 
cf. starvation, 465-466 
Fluid resuscitation 
burn shock, 543, 544, 552 
ETX shock (£. coli), dog model, 394, 
395, 398 
microvascular permeability, septic shock, 
487-488, 490 
FMLP, 166-168, 429 
Free radicals. See Antioxidant entries; Lipid 
peroxidation entries; Oxygen free rad-
icals entries 
Galactosamine, 301, 303, 306, 307 
-sensitized mice, lipid X inhibition of 
LPS neutrophil activation, 
431-432 
see also Ebselen (selenium Compound), 
protection vs. endotoxin shock in 
galactosamine-sensitized rodents 
Gamma camera, microvascular permeability, 
septic shock, 487, 491 
Gastrointestinal system in MOF, 460, 532 
Gebexate mesilate, 154-155, 389 
Gentamicin, multitherapy regimen for endo-
toxemia, pigs, 222 
Glasgow Coma Scale, 622 
Glomerular fibrin deposits, prostacyclin in 
ETX shock, 371, 374, 375 
Glucose 
cardiovascular abnormalities, septic 
shock, 447, 449-451, 454-455 
injury cf. sepsis, 470-472 
ischemia, small intestine, vascular perfu-
sion, 504-505 
oxidation, flow or catabolic phase, 
464-466 
/3-Glucuronidase,ETX, cause of mediator re-
lease in sepsis, 379 
Glutathione peroxidase, ebselen protection 
vs. ETX shock in galactosamine-sen-
sitized rodents, 282, 285, 286 
Glutathione, reduced (GSH) 
650 / Index 
antioxidant protection vs. free-radical me-
diated myocardial injury, 635-639 
oxygen radical scavengers, Prophylaxis 
and treatment, 261 
Glycerol, injury cf. sepsis, 472, 473 
Glycogen Phosphorylase a, transmembrane 
signaling perturbation, endotoxemia, 
rat hepatocyte, 404, 405, 411-413, 
416 
Granulocytes (PMNs) 
accumulation in myocardial shock is-
chemia, 63-70 
lidocaine, 65, 67-69 
oxygen free radicals, 64 
reperfusion, 65-66 
activation, 253-254, 260 
oxygen free radicals, LPS generation, 
blood, 419, 422, 424, 425 
aggregation, antioxidant drugs, 276, 278 
aprotinin, cellulareffects, 165-171 
arachidonic acid system activation, iso-
lated lung, 292, 296-298 
oxygen radicals, 296 
burn shock and resuscitation, 539-540, 
547-549 
ETX, cause of mediator release in sepsis, 
378, 379, 387, 388 
leukotriene generation, Polytrauma pa-
tients with ARDS, 311, 314-315 
limb ischemia and inflammation, 14-15 
aggregation, 11, 16 
-monocyte CSF, 432-433 
whole body inflammation, trauma patient 
autopsy study, 55, 58 
see also Elastase, granulocyte; Leuko-
cyte(s); Neutrophils 
Granulocytes, mediation of pulmonary mem-
brane damage, 75-85 
ARDS, 75, 76, 78, 83, 84 
cardiopulmonary bypass, 76-85 
complement activation during, 77-78, 
80, 84-85 
elastase release during, 81-83 
intrapulmonary Sequestration, 79-81, 
85 
MDA levels, 79-80 
oxygen free radical peroxidation, 
79-81, 83-84 
post-perfusion Syndrome, 75, 83, 84 
«i-Proteinase inhibitor, 83-84 
whole body inflammation, 84 
Granulocytes, mediation of tissue injury, 
19-28 
activation and shock lung, 23-24 
aggregation, 21-23 
complement system activation, 20-24 
endothelial damage after endotoxin acti-
vation, 25-28 
and platelets, 26 
free iron, 27-28 
frustrated phagocytosis, 19-20 
intravascular activation, 20-21 
oxygen radicals, 26-28 
pharmacology, 24-25 
Steroids, 24-26 
a-1-Proteinase inhibitor, 27 
GSH (reduced glutathione) 
antioxidant protection vs. free-radical me-
diated myocardial injury, 635-639 
oxygen radical scavengers, Prophylaxis 
and treatment, 261 
Hageman factor (factor Xu), 159, 162, 539, 
540 
Hannover Trauma Scale, 521 
Heart 
depressant factors, 599-603 
acidosis, 600 
isolated papillary muscle, 602, 603 
leucine, 601 




bolic correlations, septic shock, 
446, 454 
rate 
and atropine, in hypotensive central 
hypovolemia, 629-631 
ETX shock (E. coli), dog model, 
394-395 
myocardial dysfunction in sepsis, 
574-578, 587 
stimulant factors in shock, 599-600, 
603-607 
catecholamines and angiotensin U, 
603 
Index / 651 
histamine, 604 
inotropic, 603, 604 
MSF, shock-induced, 604-607 
ventricular function 
hypovolemic-traumatic shock, 561, 
567 
multitherapy regimen for endotox-
emia, 230,231, 233 
physiologic-metabolic correlations, 
septic shock, 444 
see also Cardiac Output; Hemodynamics; 
Myocardial entries; Nickel re-
lease, endogenous, myocardial 
damage 
Heart Performance evaluation, hypovolemic-
traumatic shock, 561-570 
cardiodynamics, Schema, 562-563 
closed-loop feed-back control circuits, 
561,569 
Computers, 568 
contractility, 567, 569 
myocardium Performance, 561 
Separation of control circuits, 569 
isolated heart-lung preparation, 
569-570 
ventricular Performance, 561, 567 
Hemodialysis, MOF, 460, 461 
Hemodynamics 
aprotinin and Cl-esterase inhibitor infu-
sion and pancreatic shock, pig, 
193-195 
arachidonic acid system activation, iso-
lated lung, 289-298 
PAP, 292-295 
BW755C in endotoxemia, 356-357 




kallikrein-kinin system activation, lung, 
E. coli septic sheep, 135, 137 
MDF release during CPB, 612-616, 
618-619 
PGE, administration in ARDS, 363-365 
see also Hyperdynamic/hypermetabolic 
State; Trypsin-induced shock, 
hemodynamics and proteolysis, 
pigs; Vascular entries; under En-
dotoxemia, multitherapy regimen, 
pigs 
Hemorrhage, atropine effect on heart rate, 
629, 630 
Heparin, extracorporeal circulation 
Cl-esterase inhibitor and elastase release, 
108 
kallikrein-kinin system activation during 
CPB, 87-89, 91 
Hepatitis, ebselen protection vs. ETX shock 
in galactosamine-sensitized rodents, 
281,284, 285 
Hepatocytes. See Transmembrane signaling 
perturbation, endotoxemia, rat 
hepatocyte 
HETE and HPETE, 40-41, 334 
Hip surgery, methylmethacrylate cement in, 
6 
Hirudin and thrombin, lung microvascular 
injury, 39 
Histamine, 162, 212, 227 
antihistamine in multitherpy regimen for 
endotoxemia, pig, 212, 213, 222, 
228 
heart Stimulation, 604 
leukotrienes and lipid mediators in ARDS 
pathogenesis, 318, 321, 322 
Hospital Trauma Index, 56 
HPLC. See Chromatography, HPLC 
5HT. See Serotonin 
Hydrogen peroxide 
injury 
cultured cells, 253-254 
lung, 238-249 
-myeloperoxidase, oxygen free radicals, 
LPS generation, blood, 422 
Hydroxyl radical, oxygen free radicals and 
lung injury, 238-241 
and iron chelators, 239-240 
4-Hydroxynonenal, lipid peroxidation prod-
ucts, cytotoxic, rat liver microsomes, 
246, 248-250 
Hyperdynamic/hypermetabolic State 
MOF, wound inflammatory mediators 
and, 525-526, 531-532 
sepsis Syndrome, 526-528, 533-534 
myocardial dysfunction in sepsis, 574, 
584, 585, 587 
652 / Index 
physiologic-metabolic correlations, septic 
shock, 404-442, 454 
Hypovolemic shock. See Heart Performance 
evaluation, hypovolemic-traumaticsh-
ock; Inotropic plasma substances, 
LMW, prolonged hypovolemic poly-
traumatic shock, dog 
Hypoxia, alveolar, arachidonic acid system 
activation, isolated lung, 294-295 
Ibuprofen, 378, 389 
MOF, wound inflammatory mediators 
and, 534 
see also BW755C (NSAID) effect on 
endotoxemia 
Ibuprofen effect on ETX-stimulated inflam-
mation, 333-344 
arachidonic acid and eicosanoids, 334, 
342, 344 
body temperature, 340-341 
cardiac index, 338, 340 
cyclooxygenase inhibition, 334, 344 
general NSAID mechanism, 334 
lymph flow, 334, 335, 337, 344 
microvascular permeability, 340, 342, 
343 
neutropenia, 333-334, 340 
oxygen consumption, 337, 339-341, 344 
plasma volume, 337 
prophylactic/therapeutic, 335 
pulmonary vascular tone, 336 
systemic vascular resistance, 337, 338, 
340,344 
Immunoelectrophoresis, rocket, 177, 180 
Infant respiratory distress Syndrome, 517, 
521 
Inflammation, whole body 
granulocyte mediators of pulmonary 
membrane damage, 84 
trauma patient autopsy study, 55-60 
complement, 59-60 
liver, 58 
MOF and ARDS, 55-60 
organ weights, 56-60 
PMNs, 55, 58 
thromboplastin and DIC, 59 
see also BW755C (NSAID) effect on en-
dotoxemia; Ibuprofen effect on 
ETX-stimulated inflammation; 
Multiple organ failure, wound in-
flammatory mediators; under Is-
chemia 
Inhalation injury. See under Burn shock and 
resuscitation 
Injury Severity Score, 622 
whole body inflammation, trauma patient 
autopsy study, 56-57 
Inositol phospholipid turnover, transmem-
brane signaling perturbation, endotox-
emia, rat hepatocyte, 401-404, 
407-409, 416 
Inotropic plasma substances,LMW, pro-
longed hypovolemic polytraumatic 
shock, dog, 591-596 
calcium-binding, 596 
HPLC, reverse phase, 594 
cf. myocardial depressant factor, 591, 
592, 596 
and papillary muscle, guinea pig bioas-
say, 592, 595 
sodium Chloride, 591-594 
see also Myocardial depressant factor 
Insulin, flow or catabolic phase, 466-469, 
472 
Interleukin-1 
changes in injury, 463, 469, 472 
MOF, wound inflammatory mediators 
and, 531-534 
Protease inhibitors in endotoxemia, 150 
Interleukin-2, 447 
Intestinal ischemia, vascular perfusion, rat, 
503-507 
Intravascular activation, granulocyte media-
tion of tissue injury, 20-21 
IP3, transmembrane signaling perturbation, 
endotoxemia, rat hepatocyte, 413-415 
Iron 
ADP-, lipid peroxidation products, cyto-
toxic, rat liver microsomes, 
247-249 
antioxidant drugs, 272 
chelators, oxygen free radicals and lung 
injury, 239-240 
free, granulocyte mediation of tissue in-
jury, 27-28 
Ischemia 
limbs, C3a and C5a as mediators of in-
flammation, 11-17 
Index / 653 
ARDS, 11 
bilirubin (liver function), 11, 13-15, 
17 
Creatinine (kidney function), 13-15, 
17 
granulocytes, 14-15 
granulocytes, aggregation, 11, 16 
oxygen radicals, 15 
platelets, 14-16 
respiratory function, 11, 13-15, 17 
myocardial shock-, granulocyte accumu-
lation, 63-70 
reperfusion, 65-66 
-reperfusion, antioxidant protection vs. 
free-radical mediated myocardial 
injury, 634-639 
Isoproterenol, myocardial dysfunction in sep-
sis, 577, 578 
Kallikrein 
aprotinin and Cl-esterase inhibitor infu-
sion and pancreatic shock, pig, 
194, 196-200 
inhibition, 193, 194, 196, 197, 199 
aprotinin inhibition, very high dosage, 
Polytrauma, 175-181 
infusion, kinin-induced pathology in 
ARDS development, pig, 127-130 
bolus injection cf. continuous infu-
sion, 128-129 
trypsin-induced shock, hemodynamics 
and proteolysis, 185-188, 191 
inhibition, 186, 189, 191 
Kallikrein-kinin system 
aprotinin and Cl-esterase inhibitor, 
159-163 
arachidonic acid system, isolated lung, 
289, 291-292 
catecholamines, multiple trauma, and 
ARDS, 477 
inhibition, Cl-esterase inhibitor and elas-
tase release, extracorporeal circu-
lation, 107-110, 113 
multitherapy regimen for endotoxemia, 
pigs, 212-215, 220-221, 227 
Protease inhibitors in endotoxemia, 149, 
152-153 
see also specific components 
Kallikrein-kinin system activation during 
aorto-coronary bypass (CPB), 87-93 
aprotinin, 87-89, 91,93 
Cl-esterase inhibitor, 89, 92, 93 
extracorporeal circulation, 87 
heparin, 87-89, 91 
kallikrein, 87-90, 92 
inhibition, 87-89, 91-93 
kininogen, HMW, 87-90 
prekallikrein, 87-90, 93 
activators, 93 
Kallikrein-kinin system activation, lung, 
E. coli septic sheep, 133-138 
antithrombin m, 134, 136-138 
bradykinin, 137-138 
hemodynamics, 135, 137 
kallikrein inhibition, 134, 136-137 
lymph flow, 134, 135, 137 
prekallikrein, 134, 136, 137 
Prothrombin, 134, 136-138 
Ketanserin, multitherapy regimen for endo-
toxemia, pigs, 212, 213, 222, 228 
Kidney 
aprotinin, very high dosage, Polytrauma, 
180-182 
Creatinine, 181 
urine Output, 180-181 
function (Creatinine), limb ischemia, C3a 
and C5a as mediators of inflamma-
tion, 13-15, 17 
glomerular fibrin deposits, prostacyclin in 
ETX shock, 371, 374, 375 
MOF, 460-462 
Kinin 
aprotinin and Cl-esterase inhibitor infu-
sion and pancreatic shock, pig, 
199 
-induced pathology in ARDS develop-
ment, kallikrein infusion, 127-130 
inhibition, Cl-esterase inhibitor and elas-
tase release, extracorporeal circu-
lation, 107-110, 113 
see also Kallikrein-kinin entries 
Kininogen 
aprotinin and Cl-esterase inhibitorinfu-
sion and pancreatic shock, pig, 
199 
ARDS, pig, 127-129 
654 / Index 
HMW 
aprotinin and Cl-esterase inhibitor, 
159, 161-162 
during CPB, 87-90 
Krebs-Henseleit Solution, 503-507 
Kupffer cells, 534 
Lactate 
ETX shock (£. coli), dog model, 394, 
396, 397 
physiologic-metabolic correlations, septic 
shock, 446, 452 
Lactoferrin, 510 
LAMS Computer Software, 335, 337 
Langendorff perrused hearts, myocardial 
dysfunction in sepsis, 577 
Leucine, heart depressant factor, 601 
Leukocyte(s) 
BW755C in endotoxemia, 347-350, 352, 
353, 357 
count, Cl-esterase inhibitor, early E. coli 
septicemia, pigs, 143, 145 
prostacyclin in ETX shock, 370, 372, 
375 
see also Elastase-approteinase inhibitor 
complex, and leukocyte counts, 
septic pig lung; Granulocytes en-
tries; Neutrophils 
Leukocytosis, MOF, wound inflammatory 
mediators and, 530-531 
Leukostasis, quantitative estimation, post-
traumatic lung cf. controls, 43-51 
ARDS and MOF, 50 
degranulation, 48-49 
dogs, 43-45, 50 
reinfusion, 44, 48, 50 
elastase, 50 
esterase stain, 45, 49 
human autopsy cases, 45-49 
diagnoses, 46-47 
labeling, 44, 45, 48, 50-51 
Leukotrienes 
alveolar cell reactions, posttraumatic lung 
failure and ARDS, 510-512 
arachidonic acid system activation, iso-
latedlung, 291,293,296 
ebselen protection vs. ETX shock in gal-
actosamine-sensitized rodents, 
281,284-286 
fibrin-neutrophil interactions, lung mi-
crovascular injury, 40-41 
MOF, wound inflammatory mediators 
and, 531 
Leukotrienes and lipid mediators in ARDS 
pathogenesis, 317-324 
andC5a, 317, 318, 320-324 
and neutrophils, 324 
and smooth muscle contraction, 
321-322 
histamine, 318, 321, 322 
PAF, 317-323 
chemical structure, 318, 319, 321 
Schema, 324 
vascular permeability, 320-322 
Leukotrienes asmediators of ETX shock and 
tissue trauma, rat, 301-307 
cysteinyl, 303-307, 323 
hepatobiliary elimination inhibited by 
ETX, 304-305, 307 
LPS, pathogenesis mechanism, 306-307 
Leukotrienes, generation, Polytrauma pa-
tients with ARDS, 311-316 
bronchoalveolar lavage, 312-314 
extravascular lung water, 312-313 
granulocytes, 311, 314-315 
HPLC, 312, 313 
RIA, 312, 313 
Lidocaine, granulocyte accumulation in myo-
cardial shock ischemia, 65, 67-69 
Limb ischemia. See under Ischemia 
Lipid(s) 
cardiovascular abnormalities, septic 
shock, 447, 452-455 
fat oxidation in injury, 464, 465, 469 
see also Leukotrienes and lipid mediators 
in ARDS pathogenesis 
Lipid peroxidation, 274, 275 
antioxidant protection vs. free-radical me-
diated myocardial injury, 633-639 
MDA, 635, 636 
oxygen free radicals and lung injury, 
239-241 
Lipid peroxidation products, cytotoxic, rat 
liver microsomes, 245-250 
ADP-iron, 247-249 
aldehyde, 245-248 
malondialdehyde, 247, 249 
Index / 655 
HPLC, 246, 247 
PUFAs, 245, 246 
4-hydroxynonenal, 246, 248-250 
toxic second messengers, 249 
Lipid X inhibition of LPS neutrophil activa-
tion, 427-434 
ETX receptor competition, 434 
galactosamine-sensitized mice, 431-432 
lungs, 431,433 
cf. other lipid A monosaccharide deriva-
tives, 427, 429, 430, 432 
oxygen free radicals, 427, 432 
Superoxide, 427-429, 431 
Lipopolysaccharide, 378, 380, 385, 387, 389 
leukotrienes as mediators of ETX shock 
and tissue trauma, 306-307 
see also Lipid X inhibition of LPS neu-
trophil activation; Oxygen free 
radicals, LPS generation, fresh hu-
man blood 
Lipoxygenäse inhibition, BW755C in endo-
toxemia, 302, 347, 358 
Liver 
cirrhosis, PGEj administration in ARDS, 
365 
cysteinyl leukotriene elimination inhibited 
by ETX, 304, 305, 307 
ebselen protection vs. ETX shock in gal-
actosamine-sensitized rodents 
enzymes, 283, 284, 286 
toxicity, 284 
function, limb ischemia, C3a and C5a as 
mediators of inflammation, 11, 
13-15, 17 
MOF, 460, 462 
Kupffer cell, 534 
wound inflammatory mediators and, 
534 
whole body inflammation, trauma patient 
autopsy study, 58 
see also Lipid peroxidation products, cy-
totoxic, rat liver microsomes; 
Transmembrane signaling pertur-
bation, endotoxemia, rat 
hepatocyte 
Lucigenin, oxygen free radicals, LPS genera-
tion, blood, 420, 422, 425 
Luminol, oxygen free radicals, LPS genera-
tion, blood, 420-424 
Lungs 
aprotinin, very high dosage, Polytrauma, 
180,182 
biochemical monitoring during CPB, 
95-104 
infant RDS, 517, 521 
lipid X inhibition of LPS neutrophil acti-
vation, 431,433 
MOF,460-462 
phospholipid profile, ARDS in Poly-
trauma patients, 517-521 
postperfusion, 100, 102, 104 
Surfactant 
ARDS, 517, 520 
phospholipids, burn shock and resus-
citation, 550-551 
ventilatory management, 455, 551 
see also Alveolar entries; Arachidonic 
acid system activation, isolated 
rabbit lung; ARDS (adult respira-
tory distress sydrome); Eglin, 
elastase inhibitor, influence on 
lung edema, septic pigs; Elastase-
ot\ -proteinase inhibitor complex, 
and leukocyte counts, septic pig 
lung; Fibrin-neutrophil interac-
tions, lung microvascular injury; 
Granulocytes, mediation of pulmo-
nary membrane damage; Leukos-
tasis, quantitative estimation, 
posttraumatic lung cf. controls; 
Oxygen free radicals and lung in-
jury, rat; Pulmonary entries; Res-
piratory entries 
Lymph flow 
BW755C in endotoxemia, 347, 349, 353-
355, 357 
ETX, cause of mediator release in sepsis, 
379, 388, 389 
ibuprofen and ETX-stimulated inflamma-
tion, 334, 335, 337, 344 
kallikrein-kinin system activation, lung, 
E. coli septic sheep, 134, 135, 137 
microvascular permeability, septic shock, 
490 
MOF, wound inflammatory mediators 
and, 531 
656 / Index 
pulmonary, fibrin-neutrophil interactions, 
lung microvascular injury, 34, 35, 
38-40 
Lysophosphatidylcholine, ARDS in Poly-
trauma, 519-521 
Lysosomal enzymes, extracorporeal circula-
tion, biochemical lung monitoring 
during CPB, 95, 96, 102-103 
lysozyme, 97, 99-100, 104 
NAG, 97-99, 101-104 
see also Elastase, granulocyte 
Lysozyme, 97, 99-100, 104 
Macaca mulatta, 115 «2-Macroglobulin, 92, 199 
binding, trypsin-induced shock, hemody-
namics and proteolysis, 191 
Cl-esterase inhibitor, early E. coli septi-
cemia, pigs, 142, 143, 145 
eglin, elastase inhibitor, and lung edema, 
septic pigs, 122-124 
Protease inhibitors in endotoxemia, 151 
Macrophage(s) 
and complement in shock, 5 
-like cell line P388D,, oxidant injury, 
254-256 
myocardial dysfunction in sepsis, 587 
Malondialdehyde (MDA) 
antioxidant protection vs. free radical me-
diated myocardial 
injury, 635-636 
formation, and antioxidant drugs, 276, 
278 
granulocyte mediators of pulmonary 
membrane damage, CPB, 79-80 
rat liver microsomes, 247, 249 
Membrane 
damage. See Granulocytes, mediation of 
pulmonary membrane damage; 
Lipid peroxidation entries 
stabilization, ibuprofen, 329 
Mercaptopropionylglycine, 276 
Mesenteric artery, superior, ischemic small 
intestine, vascular perfusion, 503 
Metabolic control changes in injury, 463-474 
flow or catabolic phase, 463, 465-469 
cf. starvation, 465-466 
cf. sepsis, 465, 469-472 
see also Hypodynamic/hypermetabolic 
State; Septic shock, physiologic 
and metabolic correlations, 
humans 
Methylmethacrylate cement in hip surgery, 6 
Methylprednisolone 
MDF release during CPB, 611, 613-615, 
617-618 
multitherapy regimen for endotoxemia, 
pigs, 212, 213, 220-222, 228 
cf. PBN, oxygen radical scavengers, Pro-
phylaxis and treatment, 263, 268 
Microsomes. See Lipid peroxidation prod-
ucts, cytotoxic, rat liver microsomes 
Microvascular injury. See Fibrin-neutrophil 
interactions, lung microvascular 
injury 
Microvascular permeability, endotoxemia/ 
septic shock, 347-352, 357, 487^91 
albumin flux, labeled, E. coli septic 
shock, 490-491 
ARDS, 487 
BW755C, 348, 354, 357 
ETX, cause of mediator release in sepsis, 
377, 379-381, 387, 388 
shear rate, 387-388 
fluid resuscitation, 487-488, 490 
gamma camera, 487, 491 
ibuprofen and ETX-stimulated inflamma-
tion, 340, 342, 343 
leukotrienes and lipid mediators in 
ARDS, 320-322 
lymph flow, 490 
plasma volume, 489-490 
Protease inhibitors, 150-151 
transcapillary escape rate, 489 
Mitochondria, 253, 260, 267 
MOF. See Multiple organ failure entries 
Monitoring. See under Extracorporeal 
circulation 
Mortality, Ni release, myocardial damage, 
623 
a-MPG, 276 
MTDQ-DA, 633, 636, 639 
Multiple organ failure (MOF, MSOF) 
and complement in shock, 3, 4, 7 
ARDS, 4, 6 
leukostasis, quantitative estimation, 50 
Index / 657 
physiologic-metabolic correlations, septic 
shock, 442,443, 451,455 
septic patients, 459-462 
whole body inflammation, trauma patient 
autopsy study, 55-60 
Multiple organ failure, wound inflammatory 
mediators, 525-535 
ARDS, 534 
burns, 525, 526, 528, 532 
infected cf. uninfected, 527 
ETX, 527-532, 534 
Gl permeability, 532 
Prostaglandins, 529-530, 532, 534, 
535 
recurrent low-dose endotoxemia, 
hemodynamics, 528-529, 531 
thromboxanes, 529-531 
hyperdynamic, hypermetabolic State, 
525-526, 531-532 





lymph flow, 531 
mediators listed, 527 
oxygen consumption, 525-527, 532 
prevention, 534-535 
ibuprofen, 534 
sheep, 527, 531 
Multiple trauma. See Aprotinin, very high 
dosage, Polytrauma; Catecholamines, 
multiple trauma, and ARDS; Inotropic 
plasma substances, LMW, prolonged 
hypovolemic polytraumatic shock, 
dog; Leukotrienes, generation, Poly-
trauma patients with ARDS; Phospho-
lipid lung profile, ARDS in 
Polytrauma patients 
Multitherapy regimen. See Endotoxemia, 
multitherapy regimen, pigs 
Muscle 
papillary, 592, 595, 602, 603 
P02 , oxygen and blood flow, regional 
differences in early sepsis, 495, 
496, 501 
skeletal, cardiovascular abnormalities, 
septic shock, 447-449 
smooth, contraction, leukotrienes and 
lipid mediators in ARDS patho-
genesis, 321-322 
see also Myocardial entries 
Myeloperoxidase, 422, 510 
Myocardial depressant factor, 591, 592, 596, 
601-604 
inotropic, 602 
release during CPB, 611-619 
aprotinin effect, 611, 613-615, 
617-618 
effects, 616-617 
hemodynamics, 612-616, 618-619 
methylprednisolone effect, 611, 
613-615, 617-618 
postperfusion Syndrome, 616 
Myocardial dysfunction in sepsis, rat, 
573-587 
jS-adrenergic Stimulation, 576-577 
isoproterenol, 577-578 
calcium homeostasis, altered, 579, 581, 
583, 584, 587 
cardiac Output, 575, 579, 584 
chronotropic effects, 576-578 
contractility, 574, 576, 579, 581. 584 
endotoxin, 387, 576, 584 
cell membrane effect, 576 
heart rate, 574-578, 587 
hyperdynamic, hypermetabolic State, 574, 
584, 585, 587 
Langendorff perfused hearts, 577 
left atrial filling pressure, 580 
macrophage, 587 
oxygen consumption, 579, 585, 586 
phosphate inadequacy, 579, 585 
physiologic-metabolic correlations, septic 
shock, 446, 454 
stroke volume, 574-576 
ventricular Performance, 573, 577, 579, 
581, 582 
compliance, 581 
see also Antioxidant protection vs. free 
radical mediated myocardial in-
jury, dogs; Nickel release, endoge-
nous, myocardial damage; under 
Granulocytes (PMNs) 
Myocardial Performance, hypovolemic-trau-
matic shock, 561 
658 / Index 
Myocardial Stimulation factor, shock-in-
duced, 604-607 
NAD, 255-257 
NADPH oxidase, 253, 260 
Naja naja cobra, 236-240 
Naloxone, 212, 213, 227, 228, 385, 389 
Neutropenia 
dialysis-associated, 21 
ibuprofen and ETX-stimulated inflamma-
tion, 333-334, 340 
Neutrophils 
chemiluminescence, alveolar cell reac-
tions, posttraumatic lung failure 
and ARDS, 510-511 
leukotrienes and lipid mediators in ARDS 
pathogenesis, 324 
oxygen free radicals and lung injury, 
235-239 
Proteinase release, 238-239 
d\ -Proteinase inhibitor bioavailability, in-
jected vs. aerosolized, 203-204 
see also Fibrin-neutrophil interactions, 
lung microvascular injury; Granu-
locytes entries; Lipid X inhibition 
of LPS neutrophil activation 
Nickel release, endogenous, myocardial 
damage, 600, 621-626 
burns, 622 
cause of death, 623 
ECG records, 621-623, 625 
EM, 622, 625 
serum levels, 621, 624 
Nitrogen loss, flow or catabolic phase, 
465-469 
No reflow phenomenon, 63 
Norepinephrine, multiple trauma, and 
ARDS, 478, 483-486 
NSAID mechanism, 334; see also BW755C 
(NSAID) effect on endotoxemia; Ibu-
profen entries 
Opiates, endogenous (endorphins), 212, 227, 
385, 389 
Organ failure. See Multiple organ failure 
entries 
Organ weights, whole body inflammation, 
trauma patient autopsy study, 56-60 
Ouabain, 581, 583 
Oxidant injury of cultured cells, 253-258 
ARDS, 253 
and ATP content, 254 
bovine aortic endothelial cells, 254-255 
DNA, SSB, 256-257 
H202, 253-254 
mouse macrophage-like cell line P388D], 
254-256 
and NAD content, 255-257 
poly-ADP-ribose Polymerase, 255-257 
Oxidative inactivation, arproteinase inhibi-
tor, injected vs. aerosolized, 203-204 
Oxygen 
consumption, 337, 339-341, 344, 500 
MOF, wound inflammatory mediators 
and, 525-527, 532 
myocardial dysfunction in sepsis, 579, 
585, 586 
physiologic-metabolic correlations, 
septic shock, 444, 454 
delivery and consumption, PGEi admin-
istration in ARDS, 361, 364-367 
pressure 
alveolo-arterial difference (AaD02), 
posttraumatic lung failure and 
ARDS, 510 
partial, 495-497, 501, 504-505 
tension/saturation, multitherapy regimen 
for endotoxemia, 232, 233 
Oxygen and blood flow, regional differences, 
early sepsis, 495-502 
arterial blood pressure, 501 
arterial oxygen transport, 499 
cardiac Output, 496, 498 
maldistribution, 501-502 
POz, 495-497 
muscle, 495-496, 501 
Oxygen free radicals 
arachidonic acid system activation, iso-
lated lung, 296 
ETX, cause of mediator release in sepsis, 
379, 380 
granulocyte 
accumulation in myocardial shock is-
chemia, 64 
mediation of tissue injury, 26-28 
limb ischemia, C3a and C5a as mediators 
of inflammation, 15 
Index / 659 
lipid X inhibition of LPS neutrophil acti-
vation, 427, 432 
peroxidation, granulocyte mediators of 
pulmonary membrane damage, 
CPB, 79-81, 83, 84 
MDA levels, 79-80 
Protease inhibitors in endotoxemia, 
150-151 
see also Lipid peroxidation entries; Oxi-
dant injury of culturedcells 
Oxygen free radicals and lung injury, rat, 
235-241 
catalase, 238, 240, 272, 274 
cobra venom factor, 236-240 
complement, 235-238 
endothelial cells, 236, 238 
H202, 238-239 
hydroxyl radical, 238-241 
and iron chelators, 239-240 
lipid peroxidation, 239-241 
neutrophils, 235-239 
Proteinase release, 328-239 
platelets, 235-236 
SOD, 238, 272, 274 
Superoxide radical, 238-239 
Oxygen free radicals, LPS generation, fresh 
human blood, 419-425 
chemiluminescence, 420-422 
lucigenin, 420, 422, 425 
luminol, 420-424 
Superoxide radical, 422 
PMN activation, 419, 422, 424, 425 
Oxygen free radical scavengers, Prophylaxis 




electron spin reponse, 261, 262, 
267-268 
cf. methylprednisolone, 263, 268 




see also Antioxidant entries 
PAF, 317-323 
chemical structure, 318, 319, 321 
Pancreatitis, 127, 128, 130 
MOF, 461 
see also Aprotinin and Cl-esterase inhibi-
tor infusion and pancreatic shock, 
Pig 
Papillary muscle, 595, 595, 602, 603 
Parenteral nutrition, injury cf. sepsis, 470 
Partial oxygen pressure (PO2) 
ischemia, small intestine, vascular perfu-
sion, 504-505 
regional differences in early sepsis, 
495-497 
muscle, 495, 496, 501 
PBN, oxygen radical scavenger, Prophylaxis 
and treatment, 261-268 
PEEP, burn shock and resuscitation, 551 
Permeability, Gl, MOF, 532; see also Micro-
vascular permeabüity, endotoxemia/ 
septic shock 
Peroxidation, lipid. See Lipid peroxidation 
entries 
PH 
heart depressant factor, acidosis, 600 
ischemia, small intestine, vascular perfu-
sion, 504-505 
Phagocytosis 
aprotinin, cellular effects, 169, 171 
frustrated, granulocyte mediation of tis-
sue injury, 19-20 
Phenyl-t-butyl-nitrone (PBN), oxygen radical 
scavenger, Prophylaxis and treatment, 
261-268 
Phosphate inadequacy, myocardial dysfunc-
tion in sepsis, 579, 585 
Phosphatide acid 
ARDS in Polytrauma, 519, 521 
transmembrane signaling perturbation, 






ARDS in Polytrauma, 517, 519-521 
transmembrane signaling perturbation, 
endotoxemia, rat hepatocyte, 402-
404, 408, 409, 416 
Phosphatidylserine, 519, 521 
Phospholipase 
660 / Index 
A2, 170 
C, transmembrane signaling perturbation, 
endotoxemia, rat hepatocyte, 404, 
407 
Phospholipid lung profile, ARDS in Poly-
trauma patients, 517-521 
bronchoalveolar lavage, 518, 520 
HPLC, 517-519, 521 
cf. infant RDS, 517, 521 
and Surfactant abnormality, 517, 520 
PIP and PIP2, transmembrane signaling per-
turbation, endotoxemia, rat hepato-
cyte, 404, 407, 409, 414 
Pituitary, 479 
Plasma 
eglin, elastase inhibitor, and lung edema, 
septic pigs, 122-123 
volume 
burn shock and resuscitation, 540-542 
microvascular permeability, septic 
shock, 489, 490 
see also Inotropic plasma substances, 
LMW, prolonged hypovolemic 
polytraumatic shock 
Plasmin inhibition, aprotinin, very high dos-
age, Polytrauma, 179 
Platelet(s) 
activating factor, 317-323 
chemical structure, 318, 319, 321 
aggregation, PGEi administration in 
ARDS, 367 
aprotinin 
cellular effects, 165, 170, 171 
and Cl-esterase inhibitor, plasma kal-
likrein-kinin system activation, 
160 
BW755C in endotoxemia, 348, 351 
Cl-esterase inhibitor, early E. coli septi-
cemia, pigs, 144 
granulocyte mediation of tissue injury, 26 
limb ischemia, C3a and C5a as mediators 
of inflammation, 14-16 
oxygen free radicals and lung injury, 
235-236 
prostacyclin in ETX shock, 370-375 
and thrombin, lung microvascular injury, 
35 
PMNs. See Granulocytes entries 
Poly-ADP-ribose Polymerase andoxidant in-
jury, 255-257 
Polytrauma scale, 510; see also Multiple 
trauma 
Poiyunsaturated fatty acids, 245-246 
4-hydroxynonenal, 246-250 
see also Arachidonic acid entries 
Postperfusion Syndrome, 75, 83, 84 
lung, 100, 102, 104 




and aprotinin, 159, 161-162, 194, 
196, 199, 200 
early E. coli septicemia, pigs, 142, 
143, 145 
and elastase release, extracorporeal 
circulation, 107-109, 113 
during CPB, 87-90, 93 
lung, E. coli septic sheep, 134, 136 
trypsin-induced shock, hemodynamics 
and proteolysis, 186, 188 
see also Kallikrein-kinin system entries 
Promethazin, multitherapy regimen for endo-
toxemia, pigs, 212, 213, 222, 228 
Propyl-gallate, 276 
Prostacyclin, 385 
Prostacyclin,intravenous, in endotoxin 
shock, rabbit, 369-375 
cyclooxygenase product, 369-370 
glomerular fibrin deposits, 371, 374, 375 
hemodialysis product, 371, 373-375 
leukocytes, 370, 372, 375 
PGI2 infusion, 362-375 
platelets, 370-375 
and thromboxane, 369-375 
vasodilation, 369 
Prostaglandin Ei administration in ARDS, 
septic and post-surgery patients, 
361-367 
cardiac index, 363, 365-367 
cardiac Output, 361 
cirrhosis, 365 
hemodynamics, 363-365 
oxygen delivery and consumption, 361, 
364-367 
plateletaggregation, 367 
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Prostaglandins, 15, 16, 212, 222, 305, 307 
arachidonic acid system activation, iso-
lated lung, 289, 291, 294-296 
flow or catabolic phase, 469 
MOF, ETX and, 529-530, 532, 534, 535 
PGI2 infusion in ETX shock, 372-375 
Protease inhibitors in endotoxemia, 149-155 
arantiprotease, 151-152 
blood coagulation cascade, 153-154 
Cl-esterase inhibitor, 153 
interleukin-1, 150 
kallikrein-kinin system, 149, 152-153 
a2-macroglobulin, 151 
microvascular permeability, 150-151 
neutrophils, oxygen free radicals and lung 
injury, 238-239 
oxygen free radicals, 150-151 
proteases in endotoxemia, 149-151 
see also Endotoxemia, multitherapy regi-
men, pigs; specific proteases and 
inhibitors 
arProteinase inhibitor, 151-152, 253 
deficiency, 207 
granulocyte mediation of tissue injury, 27 
pulmonary, 83-84 
oc\ -Proteinase inhibitor bioavailability, in-
jected vs. aerosolized, dogs, 203-209 
ARDS, 203-204 
bronchoalveolar lavage, 203-205 
bronchoscopy, 205 
neutrophils, 203-204,207 
oxidative inactivation, 203-204 
pulmonary penetration, 204-209 
Protein exchange, fibrin-neutrophil interac-
tions, lung microvascular injury, 34, 
35, 39 
Protein kinase C, transmembrane signaling 
perturbation, endotoxemia, rat hepato-
cyte, 403 
Proteolysis inducing factor, 447; see also 
Trypsin-induced shock, hemody-
namics and proteolysis, pigs 
Prothrombin, kallikrein-kinin system activa-
tion, lung, E. coli septic sheep, 134, 
136-138 
Pseudomembranes, inhalation injury, 547 
Pseudomonas, 378 
aeruginosa, 295 
Pulmonary artery pressure 
arachidonic acid system activation, iso-
lated lung, 292-295 
BW755C in endotoxemia, 353, 357 
ETX shock (E. coli), dog model, 394, 
395, 398 
multitherapy regimen for endotoxemia, 
hemodynamics, 230 
Pulmonary capillary wedge pressure, 232 
Pulmonary compliance, burn shock and re-
suscitation, 550 
Pulmonary edema, Cl-esterase inhibitor, 
early E. coli septicemia, pigs, 144; 
see also Eglin, elastase inhibitor, in-
fluence on lung edema, septic pigs 
Pulmonary lymph flow, fibrin-neutrophil in-
teractions, lung microvascular injury, 
34, 35, 38-40 
Pulmonary membrane damage. See under 
Granulocytes, mediation of pulmonary 
membrane damage 
Pulmonary vascular resistance. See under 
Vascular resistance 
Pulmonary vasculartone, ibuprofen and 
ETX-stimulated inflammation, 336 
Pyruvate dehydrogenase, cardiovascular ab-
normalities, septic shock, 447-449, 
451-452 
Quin-2, calcium measurement, 405 
Radioimmunoassay, leukotriene generation, 
Polytrauma patients with ARDS, 312, 
313 
Regional flow. See Oxygen and blood flow, 
regional differences, early sepsis 
Reperfusion 
granulocyte accumulation in myocardial 
shock ischemia, 65-66 
ischemia-, antioxidant protection vs. free 
radical mediated myocardial in-
jury, 634-639 
Resistance. See Vascular resistance 
Respiratory function, limb ischemia, C3a and 
C5a as mediators of inflammation, 11, 
13-15, 17 
662 / Index 
Respiratory quotient, flow or catabolic 
phase, 464, 465 
Salmonella 
abortus equi, 282, 421, 423 
minnesota, 301, 303 
Scavengers. See Antioxidant entries; Oxygen 
free radical scavengers,prophylaxis 
and treatment of experimental shock, 
rat 
Second messengers, toxic, lipid peroxidation 
products, 249 
Selenium. See Ebselen (selenium Com-
pound), protection vs. endotoxin 
shock in galactosamine-sensitized 
rodents 
Sepsis/septicemia 
cf. changes in injury, 465, 467-472 
multiple organ failure, 459-462 
Syndrome, MOF, wound inflammatory 
mediators and, 526-528, 533-534 
see also Cl-esterase inhibitor, early E. 
coli septicemia, pigs; Eglin, elas-
tase inhibitor, influence on lunge-
dema, septic pigs; Elastase-ap 
proteinase inhibitor complex, and 
leukocyte counts, septic pig lung; 
Kallikrein-kinin system activation, 
lung, E. coli septic sheep; Micro-
vascular permeability, endotox-
emia/septic shock; Myocardial 
dysfunction in sepsis, rat; Oxygen 
and blood flow, regional differ-
ences, early sepsis; Prostaglandin 
Ei administration in ARDS, septic 
and post-surgery patients 
Septic shock, ibuprofen, increased survival, 
327-330 
Septic shock, physiologic and metabolic cor-
relations, humans, 439-456 
A-D states, 446 
ARDS, 441, 446 
cardiac abnormalities, metabolic basis, 
446-453, 455^56 
hemodynamics, 440-442, 454 
cardiac Output, 440-442 
vascular tone, 442, 444 
lactate, 446, 452 
MOF, 442, 443,451,455 
Protease inhibitors, 453 
protein reprioritization, 453-454 
myocardial depression, 446, 454 
patterns of sepsis, cf. reference control 
State, 443-446 
oxygen consumption, 444, 454 
ventricular function, 444 
therapy, 454-456 
ventilatory management, 455 
see also Endotoxin shock 
Serotonin (5HT), 162, 212, 227 
antagonist ketanserin, 212, 213, 222, 228 
Signaling. See Transmembrane signaling per-
turbation, endotoxemia, rathepatocyte 
Simplified Acute Physiologic Score, 622 
Small intestine, ischemia, vascular perfusion, 
503-507 
SMAO, oxygen radical scavengers, Prophy-
laxis and treatment, 262-264 
Sodium Chloride, 591-594 
Sphingomyelin, ARDS in Polytrauma, 
519-521 
Spin resonance, oxygen radical scavengers, 
Prophylaxis and treatment, 261, 262, 
267, 268 
Staphylococcal a-toxin, 295-296 
Starvation cf. flow or catabolic phase of in-
jury, 465-466 
Steroids, granulocyte mediation of tissue in-
jury, 24-26; see also specific Steroids 
Superoxide dismutase (SOD), 428, 429 
antioxidant protection vs. free radical 
mediated 
myocardial injury, 635-639 
aprotinin, cellular effects, 166 
and lung injury, 238, 272, 274 
prophylaxis/treatment, 261 
Superoxide radical 
aprotinin, cellular effects, 165, 166, 169 
lipid X inhibition of LPS neutrophil acti-
vation, 427-429, 431 
LPS generation, blood, 422 
and lung injury, 238-239 
see also Oxygen free radicals entries 
Surgery, hip, 6; see also Prostaglandin Ei 
administration in ARDS, septic and 
post-surgery patients 
Index / 663 
Survival 
aprotinin and Cl esterase inhibitor infu-
sion and pancreatic shock, pig, 
193 
ibuprofen increases, 327-330 
T cells, 380, 388 
Temperature, body. See Body temperature 
Thrombin 
catecholamines, multiple trauma, and 
ARDS, 479, 480, 485, 486 
and fibrin-neutrophil interactions, lung 
microvascular injury, 33-41 
Thromboplastin, 59 
Thromboxanes, 305, 307 
arachidonic acid system activation, iso-
latedlung, 291,293-297 
burn shock and resuscitation, 541, 548 
BW755C in endotoxemia, 347, 350, 352, 
355-357 
ETX, cause of mediator release in sepsis, 
382 
MOF, ETX and, 529-531 
prostacyclin in ETX shock, 369-375 
Thromboxane synthetase inhibitors, rat ETX, 
328-329 
TNF, 469, 472 
a-Tocopherol, 261, 272, 276 
Transferrin, 272, 274 
Transmembrane signaling perturbation, en-
dotoxemia, rat hepatocyte, 401-416 
aradrenergic receptors, 406-407, 415 
Ca2+, 401-405, 409-410, 413-416 
IP3-stimulated release, 413-415 




glycogen Phosphorylase a, 404, 405, 
411-413,416 
inositol phospholipid turnover, 401-404, 
407-409 
phosphatidic acid, 402, 404, 408 
phosphatidylinositol, 402^04, 408-
409, 416 
PIP and PIP2, 404, 407-409, 414 
protein kinase C, 403 
phospholipase C, 404, 407 
Vasopressin, 402, 404, 407-412, 415 
receptors, 405-406, 415 
Trauma. See Heart Performance evaluation, 
hypovolemic-traumatic shock; Leu-
kostasis, quantitative estimation, post-
traumatic lung cf. controls; 
Leukotrienes as mediators of ETX 
shock and tissue trauma, rat; Multiple 
trauma; under Inflammation, whole 
body 
Trauma scores, catecholamines, and ARDS, 
478, 480, 484 
Triglyceride abnormalities, septic shock, 
447, 452^55 
Trypsin-induced shock, hemodynamics and 
proteolysis, pigs, 185-192 
blood pressure (MAP), 189-191 
cardiac Output, 189-191 
chromogenic peptide Substrate analysis, 
185, 186, 191 
kallikrein, 185-188, 191 
inhibition, 186, 188, 191 
a2-macroglobulin Dinding, 191 
prekallikrein, 186, 188 
trypsin, plasma activity, 186, 187 
vascular resistance, systemic, 190-191 
Tyrosine, 442 
Urinary excretion 
eglin, septic pigs, 122-123 
very high dosage aprotinin, Polytrauma, 
180-181 
Vagal activity, atropine effect on heart rate, 
629, 631 
Vascular perfusion, intestinal ischemia, rat, 
503-507 




ETX, cause of mediator release in sepsis 
peripheral, 377, 381, 382, 385 
systemic, 377 
ibuprofen and ETX-stimulated inflamma-
tion, 337, 338, 340, 344 
multitherapy regimen for endotoxemia, 
hemodynamics, 216, 218, 219, 
230 
pulmonary 
664 / Index 
multitherapy regimen for endotox-
emia, hemodynamics, 218, 
220, 230, 231 
PGE1 administration in ARDS, 363, 
365-367 
systemic, ETX shock (£. coli), dog 
model, 3%, 397 
trypsin-induced shock, hemodynamics 
and proteolysis, 190, 191 
Vascular tone, physiologic-metabolic corre-
lations, septic shock, 442, 444 
Vasopressin, 382, 601 
transmembrane signaling perturbation, 
endotoxemia, rat hepatocyte, 402, 
404, 407-412, 415 
receptors, 405-406, 415 
Vena cava superior, lung monitoring during 
CPB, 96-98, 101, 102, 104 
Ventilatory management 
inhalation injury, burn shock and resusci-
tation, 551 
physiologic-metabolic correlations, septic 
shock, 455 
Ventricular Performance 
hypovolemic-traumatic shock, 561, 567 
multitherapy regimen for endotoxemia, 
230, 231, 233 
myocardial dysfunction in sepsis, 573, 
577, 579, 581, 582 
compliance, 581 
physiologic-metabolic correlations in sep-
tic shock, 444 
Verapamil, 581, 583, 584 
burn shock and resuscitation, 542 
White blood cells. See Leukocyte(s); specific 
types 
Wound. See Multiple organ failure, wound 
inflammatory mediators 
Xanthine oxidase, 260 
ZAP, 166-168 
